Список проголосовавших за комментарий " On The Wires<ul><li>Rockwell Medical (<strong>RMTI</strong>) announced today that poster and oral presentations for Triferic have been selected by the Annual Dialysis Conference for presentation at their Annual Meeting, March 11-14, 2017 in Long Beach, CA. Triferic is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Triferic is the only FDA approved therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients.</li><li>Ross Stores (<strong>ROST</strong>) opened 23 Ross Dress for Less and five dd's DISCOUNTS stores across 15 different states in February and March. These new locations are part of the Company's plans to add approximately 70 Ross and 20 dd's DISCOUNTS locations during 2017.</li><li>Bristol-Myers Squibb (<strong>BMY</strong>) and Pfizer (<strong>PFE</strong>) announced that eight abstracts have been accepted for presentation at the American College of Cardiology 66th Annual Scientific Session, taking place March 17-19 in Washington, D.C. In addition to post-hoc analyses from the pivotal Phase 3 ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) trial, the Bristol-Myers Squibb and Pfizer Alliance will present real-world data analyses that illustrate the Alliance's ongoing commitment to understanding the use of direct oral anticoagulants, including Eliquis (apixaban), in routine clinical practice.</li><li>Applied Optoelectronics (<strong>AAOI</strong>) announced the development of Electro-absorption Modulated Lasers operating at a data rate of 10 Gigabits per second.</li><li>Global Medical REIT (<strong>GMRE</strong>) announced today that the Company has increased the commitment amount on the previously-announced senior revolving credit facility with BMO Harris Bank N.A. to $200 million plus an accordion feature that allows for up to an additional $50 million of principal amount subject to certain conditions. This Credit Facility is being increased in response to strong interest from the eight Credit Facility syndicate members. BMO Capital Markets, SunTrust Robinson Humphrey, and Citizens Bank acted as Joint Lead Arrangers and Joint Book runners on the transaction. The lenders under the Credit Facility include BMO Harris Bank N.A., Citizens Bank N.A., SunTrust Bank, The Huntington National Bank, Comerica Bank, KeyBank National Association, Franklin Synergy Bank and Branch Banking and Trust Company.</li><li>Amyris (<strong>AMRS</strong>) announced that Sumitomo Rubber Industries has adopted liquid farnesene rubber (LFR) as a performance enhancing additive for use in the production of its latest Dunlop-branded Winter Maxx 02 tires. LFR is a liquid rubber developed by Kuraray Co., using Amyris's biologically derived Biofene® branded farnesene. The Winter Maxx 02 represents the brand's best tire to date for on-ice and snow-braking performance and for durability. LFR's breakthrough performance enhancement will be available across Dunlop's entire Winter Maxx 02 portfolio of 91 sizes.</li><li>Evoke Pharma (<strong>EVOK</strong>) announced that the underwriter of its previously announced public offering of approximately 2.4 million shares of its common stock has exercised in full its option to purchase an additional 362,068 shares of common stock, at a price to the public of $2.90/share. The issuance of the additional shares closed on Friday, March 3, 2017, and all of the shares were sold by Evoke. The exercise brings the total gross proceeds from the offering to approx. $8.0 mln, before underwriting discounts and commissions and estimated offering costs. Evoke intends to use the net proceeds from the offering to fund clinical development, pre-approval and pre-commercialization activities for Gimoti, including the planned comparative exposure trial and planned NDA submission, and for working capital and general corporate purposes.</li><li>IAMGOLD (<strong>IAG</strong>) announced the signature of a power purchase agreement among IAMGOLD Essakane SA, EREN Renewable Energy SA, AREN ENERGY (PTY) Ltd. and Essakane Solar SAS to begin the development of a 15 MWp solar power plant in 2017 for the Company's Essakane mine in Burkina Faso. The agreement is for an initial period of up to 15 years. The mine is located about 330 kilometers northeast of the Burkinabe capital city, Ouagadougou. In the project's first phase, 15 MWp of solar capacity would be built and the hybridization of IAMGOLD Essakane SA's HFO power plant will allow savings of approximately six million liters of fuel and a reduction of 18,500 tonnes of CO2 per year.</li><li>Hughes Network Systems, a subsidiary of EchoStar (<strong>SATS</strong>) announced that its Defense and Intelligence and Systems Division (DISD) has been awarded a contract by General Atomics Aeronautical Systems, Inc. (GA-ASI) to work with the company to provide satellite communications on the «Type-Certifiable» Predator B (TCPB) Remotely Piloted Aircraft (RPA) system, which provides the basis for the United Kingdom's Protector programme.</li><li>FirstEnergy Nuclear Operating Company, a subsidiary of FirstEnergy (<strong>FE</strong>), announced its Perry Nuclear Power Plant in Perry, Ohio, shut down early on Sunday, March 5, for scheduled refueling, maintenance and a transformer replacement that is expected to enhance reliability.</li><li>ARCA biopharma (<strong>ABIO</strong>) announced that the 175th patient has been randomized into GENETIC-AF, a seamless design Phase 2B/3 clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF).</li><li>PositiveID Corporation (<strong>PSID</strong>) announced that its Thermomedics Inc. subsidiary, which markets the Caregiver non-contact thermometer, has entered into a new distribution agreement with National Distribution & Contracting, Inc. («NDC»). Through this new warehouse vendor agreement, NDC will purchase units of Caregiver and distribute it to its member distributors serving the acute care, alternate site, long-term care and home health segments.</li><li>Esperion Therapeutics (<strong>ESPR</strong>) announced Brian A. Ference, M.D., M.Phil., M.Sc., F.A.C.C., Associate Professor of Medicine, Wayne State University School of Medicine, will present results from Mendelian randomization studies conducted to evaluate the effect of lower LDL-C mediated by genetic variants in the ATP Citrate Lyase (ACL) gene on the risk of cardiovascular events. The abstract, «Genetic Target Validation for ATP-Citrate Lyase Inhibition» will be presented in an oral presentation during the American College of Cardiology 66th Annual Scientific Session on Sunday, March 19, 2017 at 8:51am ET at the Walter E. Washington Convention Center, Washington, DC in Room 147A.</li></ul>"